

Table C-1. General information about studies included for Key Question 1B

Study	Country/Site	Number of Patients Enrolled	Number of Patients at Final Followup	Patient Inclusion Criteria	Patient Exclusion Criteria	Treatment	Study Duration
Geruschat et al. 2015 ¹	U.S.; Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD	26	26	Enrolled in the Argus II Retinal Prostheses System clinical trial. Not explanted, and accepted participation in this pilot study of FLORA (assessment instrument)	NR	Argus II	Half had been followed for an average of 3.3 years, and half for an average of 1.7 years
Bittner et al. 2011 ²	U.S.; Lions Vision Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD	20	20	Represented in a database of previous research subjects at the center and from referrals by the Low Vision Clinic. Lived within 1.5 hour drive, not undergoing treatment for eye disease, vision likely to remain stable through 3 months	NR	None	3 months
Chow et al. 2010 ³	U.S.; Rush University Medical Center in Chicago, IL	18	18	Acuity 20/200 or worse in the better eye, and/or visual field diameter 20 degrees or less as measured by Goldmann perimetry or Humphrey field analyzer. Medically stable vision during 2–4 months of followup.	NR	None	4 months
Kiser et al. 2005 ⁴	U.S.; Lions Vision Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD	78	78 but some data points had fewer patients	Legally blind, best corrected visual acuity 20/200 or worse in the better eye, and/or visual field diameter 20 degrees or less, informed consent, judgment that their condition would not change over the 4–5 month study period.	NR	None	5 months

FLORA=Functional Low-Vision Observer Rated Assessment; NR=not reported